NEW_Molecular diagnoses of pediatric high grade gliomas: Status 2021

Question Title

* 1. How has your infrastructure changed for diagnostics of brain tumors since 2015 after revision of the WHO Classification of Central Nervous system (CNS) tumors?

There have been no changes

There have been only few minor changes

There have been some moderate changes

There have been significant changes

There have been no changes

There have been only few minor changes

There have been some moderate changes

There have been significant changes

Question Title

* 2. Could you shortly describe these infrastructural changes?

Some or more molecular diagnostics available

Immunohistochemistry as surrogate techniques for molecular diagnoses available

Collaboration with molecular genetic lab available

Other (please specify)

Question Title

* 3. Are you currently able to do molecular analyses for brain tumor diagnoses according to the 2016 WHO Classification of CNS Tumors?

Yes

Only partly

No

Question Title

* 4. In your practice, do you have molecular testing for the following alterations in regards to molecular diagnostics of high grade gliomas (and if you do, please indicate which)

H3K27M status

H3K27 trimethylation (H3K27me3) status

IDH mutation status

H3G34 status

BRAF V600E status

ALK/ROS/NTRK gene fusions

1p19q codeletions

Methylation array

Gene panel sequencing

None of the mentioned molecular testings

Question Title

* 5. In what country do you work?

Other (please specify)